S&P 500   3,321.96 (-1.04%)
DOW   27,733.44 (-0.60%)
QQQ   265.46 (-1.80%)
AAPL   106.88 (-3.14%)
MSFT   198.24 (-2.30%)
FB   252.56 (-0.89%)
GOOGL   1,449.56 (-2.52%)
AMZN   2,938.38 (-2.34%)
NVDA   484.20 (-2.88%)
TSLA   435.29 (+2.80%)
BABA   272.47 (-1.18%)
CGC   16.42 (+0.12%)
GE   6.98 (-0.99%)
MU   50.69 (-0.57%)
AMD   74.56 (-2.60%)
T   29.06 (-0.03%)
F   7.27 (-0.14%)
ACB   6.60 (-4.21%)
GILD   64.62 (-0.65%)
NFLX   464.12 (-1.29%)
DIS   129.37 (-0.65%)
BAC   25.48 (+0.51%)
BA   163.36 (-2.49%)
S&P 500   3,321.96 (-1.04%)
DOW   27,733.44 (-0.60%)
QQQ   265.46 (-1.80%)
AAPL   106.88 (-3.14%)
MSFT   198.24 (-2.30%)
FB   252.56 (-0.89%)
GOOGL   1,449.56 (-2.52%)
AMZN   2,938.38 (-2.34%)
NVDA   484.20 (-2.88%)
TSLA   435.29 (+2.80%)
BABA   272.47 (-1.18%)
CGC   16.42 (+0.12%)
GE   6.98 (-0.99%)
MU   50.69 (-0.57%)
AMD   74.56 (-2.60%)
T   29.06 (-0.03%)
F   7.27 (-0.14%)
ACB   6.60 (-4.21%)
GILD   64.62 (-0.65%)
NFLX   464.12 (-1.29%)
DIS   129.37 (-0.65%)
BAC   25.48 (+0.51%)
BA   163.36 (-2.49%)
S&P 500   3,321.96 (-1.04%)
DOW   27,733.44 (-0.60%)
QQQ   265.46 (-1.80%)
AAPL   106.88 (-3.14%)
MSFT   198.24 (-2.30%)
FB   252.56 (-0.89%)
GOOGL   1,449.56 (-2.52%)
AMZN   2,938.38 (-2.34%)
NVDA   484.20 (-2.88%)
TSLA   435.29 (+2.80%)
BABA   272.47 (-1.18%)
CGC   16.42 (+0.12%)
GE   6.98 (-0.99%)
MU   50.69 (-0.57%)
AMD   74.56 (-2.60%)
T   29.06 (-0.03%)
F   7.27 (-0.14%)
ACB   6.60 (-4.21%)
GILD   64.62 (-0.65%)
NFLX   464.12 (-1.29%)
DIS   129.37 (-0.65%)
BAC   25.48 (+0.51%)
BA   163.36 (-2.49%)
S&P 500   3,321.96 (-1.04%)
DOW   27,733.44 (-0.60%)
QQQ   265.46 (-1.80%)
AAPL   106.88 (-3.14%)
MSFT   198.24 (-2.30%)
FB   252.56 (-0.89%)
GOOGL   1,449.56 (-2.52%)
AMZN   2,938.38 (-2.34%)
NVDA   484.20 (-2.88%)
TSLA   435.29 (+2.80%)
BABA   272.47 (-1.18%)
CGC   16.42 (+0.12%)
GE   6.98 (-0.99%)
MU   50.69 (-0.57%)
AMD   74.56 (-2.60%)
T   29.06 (-0.03%)
F   7.27 (-0.14%)
ACB   6.60 (-4.21%)
GILD   64.62 (-0.65%)
NFLX   464.12 (-1.29%)
DIS   129.37 (-0.65%)
BAC   25.48 (+0.51%)
BA   163.36 (-2.49%)
Log in
NYSE:TARO

Taro Pharmaceutical Industries Stock Forecast, Price & News

$58.75
-1.29 (-2.15 %)
(As of 09/18/2020 12:47 PM ET)
Add
Compare
Today's Range
$58.75
Now: $58.75
$59.58
50-Day Range
$57.42
MA: $61.82
$67.99
52-Week Range
$56.07
Now: $58.75
$99.69
Volume340 shs
Average Volume38,294 shs
Market Capitalization$2.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.73
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.
Read More
Taro Pharmaceutical Industries logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone914-345-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$644.77 million
Cash Flow$7.10 per share
Book Value$55.15 per share

Profitability

Net Income$244.24 million

Miscellaneous

Employees1,464
Market Cap$2.25 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$58.75
-1.29 (-2.15 %)
(As of 09/18/2020 12:47 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

How has Taro Pharmaceutical Industries' stock price been impacted by COVID-19 (Coronavirus)?

Taro Pharmaceutical Industries' stock was trading at $64.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TARO stock has decreased by 6.8% and is now trading at $60.04.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Taro Pharmaceutical Industries?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Taro Pharmaceutical Industries
.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Taro Pharmaceutical Industries
.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) released its quarterly earnings results on Wednesday, July, 29th. The company reported ($11.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.16 by $12.53. The firm earned $117.63 million during the quarter, compared to analysts' expectations of $158.35 million. Taro Pharmaceutical Industries had a positive return on equity of 10.51% and a negative net margin of 42.73%.
View Taro Pharmaceutical Industries' earnings history
.

What price target have analysts set for TARO?

1 analysts have issued twelve-month price targets for Taro Pharmaceutical Industries' stock. Their forecasts range from $82.00 to $82.00. On average, they expect Taro Pharmaceutical Industries' share price to reach $82.00 in the next year. This suggests a possible upside of 36.6% from the stock's current price.
View analysts' price targets for Taro Pharmaceutical Industries
.

Who are some of Taro Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals PLC- (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the following people:
  • Mr. Uday V. Baldota, CEO & Director (Age 49)
  • Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)
  • Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)
  • Mr. Itzik Baruch, VP of Technical Services (Age 56)
  • Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72)

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (1.73%), Krensavage Asset Management LLC (1.36%), Brandes Investment Partners LP (0.85%), APG Asset Management N.V. (0.21%), CLARET ASSET MANAGEMENT Corp (0.15%) and UBS Group AG (0.12%).

Which major investors are selling Taro Pharmaceutical Industries stock?

TARO stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., CLARET ASSET MANAGEMENT Corp, Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., Robeco Institutional Asset Management B.V., California Public Employees Retirement System, Plaisance Capital LLC, and PDT Partners LLC.

Which major investors are buying Taro Pharmaceutical Industries stock?

TARO stock was acquired by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP, UBS Group AG, Krensavage Asset Management LLC, FMR LLC, Aigen Investment Management LP, New York State Common Retirement Fund, State of Tennessee Treasury Department, and Empirical Finance LLC.

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $60.04.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $2.30 billion and generates $644.77 million in revenue each year. The company earns $244.24 million in net income (profit) each year or $6.35 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is www.taro.com.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 914-345-9000 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.